DWC 202313
Alternative Names: DWC-202313Latest Information Update: 12 Jan 2024
At a glance
- Originator Daewoong Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 27 Oct 2023 Phase-I clinical trials in Unspecified (In volunteers) in South Korea (PO) (NCT06119958)